Changes in Metabolic and Blood Pressure Outcomes With Semaglutide Across Chronic Kidney Disease Stages: A Post Hoc Analysis of the FLOW Trial

Diabetes, obesity & metabolism · 2026 Nov 3 · Friedman AN, Basile J, Busch R et

By Maren Holt · Senior Reporter, GLP-1

Nov 2 19:00 ETSource: Diabetes, obesity & metabolism

From the source

Changes in Metabolic and Blood Pressure Outcomes With Semaglutide Across Chronic Kidney Disease Stages: A Post Hoc Analysis of the FLOW Trial
Diabetes, obesity & metabolism · 2026 Nov 3 · Friedman AN, Basile J, Busch R et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42977539/